58.98
전일 마감가:
$58.83
열려 있는:
$58.83
하루 거래량:
458.98K
Relative Volume:
0.13
시가총액:
$26.14B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
30.89
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
+2.94%
1개월 성능:
+4.89%
6개월 성능:
+44.77%
1년 성능:
+60.83%
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
58.98 | 26.08B | 2.44B | 1.36B | 574.14M | 1.9093 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.73 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
675.04 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
894.34 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.71 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
281.14 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RPRX|Royalty Pharma PLC|Price:58.830|Chg%:-0.190 - TradingKey
Royalty Pharma PLC (RPRXN) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Dai ichi Life Insurance Company Ltd Has $6.19 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Dorsey Asset Management LLC Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Lowers Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma Plc Class A Revenue Breakdown – TRADEGATE:RPD - TradingView
Royalty Pharma PLC (RPRXN) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Shares Sold by KBC Group NV - MarketBeat
RPHC5035520 Bond Profile — Key Metrics - TradingView
ABN Amro Investment Solutions Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRXN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRXN) Earnings Dates, Call Summary & Reports - TipRanks
RPHC6166014 Bond Profile — Key Metrics - TradingView
Royalty Pharma PLC (RPRX) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Inceptionr LLC Increases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
CI Investments Inc. Has $8.33 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RPHC5222528 Bond Profile — Key Metrics - TradingView
RPHC6166014 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5035520 Bond Risk Profile - TradingView
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK
RPHC5237354 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237354 Bond Risk Profile - TradingView
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
RPHC5237354 Bond Profile — Key Metrics - TradingView
RPHC5035520 Bond Coupon Profile — Rate & Payments - TradingView
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
Royalty Pharma PLC (RPRX) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
177,500 Shares in Royalty Pharma PLC $RPRX Acquired by Andra AP fonden - MarketBeat
Press Release: Royalty Pharma Declares Third Quarter 2026 Dividend - 富途牛牛
Royalty Pharma PLC (RPRXN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
RPHC6166013 Bond Risk Profile - TradingView
RPHC6166013 Bond Profile — Key Metrics - TradingView
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com UK
Royalty Pharma PLC (RPRX) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPRX) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com South Africa
Royalty Pharma PLC (RPRX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
로열티 파마 주식 (RPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.52 |
100,000 |
5,651,813 |
459,399 |
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.46 |
30,000 |
1,693,658 |
40,000 |
자본화:
|
볼륨(24시간):